Ibero-American Consensus Review and Incorporation of New Biomarkers for Clinical Practice in Colorectal Cancer

Descripción del Articulo

Advances in genomic technologies have significantly improved the management of colorectal cancer (CRC). Several biomarkers have been identified in CRC that enable personalization in the use of biologic agents that have shown to enhance the clinical outcomes of patients. However, technologies used fo...

Descripción completa

Detalles Bibliográficos
Autores: Bonilla, CE, Montenegro, P, O-Connor, JM, Hernando-Requejo, O, Aranda, E, Pinto-Llerena, J, Llontop, A, Gallardo-Escobar, J, Diaz-Romero, MDC, Bautista-Hernandez, Y, Graña-Suarez, B, Batagelj, EJ, Wali-Mushtaq, A, Garcia-Foncillas, J
Formato: revisión
Fecha de Publicación:2023
Institución:Instituto Nacional de Enfermedades Neoplásicas
Repositorio:INEN-Institucional
Lenguaje:inglés
OAI Identifier:oai:repositorio.inen.sld.pe:inen/212
Enlace del recurso:https://repositorio.inen.sld.pe/handle/inen/212
Nivel de acceso:acceso abierto
Materia:biomarkers
colorectal
genomic
multidisciplinary
screening
https://purl.org/pe-repo/ocde/ford#3.02.21
Descripción
Sumario:Advances in genomic technologies have significantly improved the management of colorectal cancer (CRC). Several biomarkers have been identified in CRC that enable personalization in the use of biologic agents that have shown to enhance the clinical outcomes of patients. However, technologies used for their determination generate massive amounts of information that can be difficult for the clinician to interpret and use adequately. Through several discussion meetings, a group of oncology experts from Spain and several Latin American countries reviewed the latest literature to provide practical recommendations on the determination of biomarkers in CRC based on their clinical experience. The article also describes the importance of looking for additional prognostic biomarkers and the use of histopathology to establish an adequate molecular classification. Present and future of immunotherapy biomarkers in CRC patients are also discussed, together with several techniques for marker determination, including liquid biopsy, next-generation sequencing (NGS), polymerase chain reaction (PCR), and fecal immunohistochemical tests. Finally, the role of Molecular Tumor Boards in the diagnosis and treatment of CRC is described. All of this information will allow us to highlight the importance of biomarker determination in CRC. © 2023 by the authors.
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).